Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VOR
stocks logo

VOR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.060
-87.95%
--
--
-1.653
-68.21%
--
--
-1.643
-99.35%
Estimates Revision
Stock Price
Go Down
down Image
-78.75%
In Past 3 Month
Wall Street analysts forecast VOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VOR is 40.00 USD with a low forecast of 9.00 USD and a high forecast of 64.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast VOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VOR is 40.00 USD with a low forecast of 9.00 USD and a high forecast of 64.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.330
sliders
Low
9.00
Averages
40.00
High
64.00
Current: 8.330
sliders
Low
9.00
Averages
40.00
High
64.00
Wedbush
Martin Fan
Neutral
initiated
$9
2025-11-25
Reason
Wedbush
Martin Fan
Price Target
$9
2025-11-25
initiated
Neutral
Reason
Wedbush analyst Martin Fan assumed coverage of Vor Bio with a Neutral rating with a price target of $9, up from 40c. The firm notes Vor's lead candidate telitacicept is a BAFF/APRIL ligand trap approved in China for systemic lupus erythematosus, rheumatoid arthritis, and myasthenia gravis. Wedbush sees read-through to all development indications should telitacicept yield comparable efficacy to leading MG and SjD candidates in global trials. However, considering the company's reliance on a single asset and a long timeline before first data outside of China, the firm recommends investors remain on the sidelines until global MG data emerge in 2027.
H.C. Wainwright
Buy
downgrade
$55 -> $32
2025-11-14
Reason
H.C. Wainwright
Price Target
$55 -> $32
2025-11-14
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Vor Bio to $32 from $55 and keeps a Buy rating on the shares. The firm cites share dilution from the capital raise and adjustments to reflect the company's opportunity in Sjogren's disease for the target cut.
H.C. Wainwright
H.C. Wainwright
NULL
to
Buy
upgrade
$3 -> $55
2025-10-29
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$3 -> $55
2025-10-29
upgrade
NULL
to
Buy
Reason
H.C. Wainwright adjusted the firm's price target on Vor Bio to $55 from $3 and keeps a Buy rating on the shares, telling investors that its price target increase is driven primarily by the much lower diluted share count following the 1-for-20 reverse stock split that took effect in Q3. The firm believes the data from the Phase 3 study with telitacicept as a therapy for primary Sjogren's disease conducted in China is "encouraging" and not only de-risks the drug, which is being evaluated in an ongoing U.S. Phase 3 study as a therapy for generalized myasthenia gravis, but also provides Vor with "another shot on goal," the analyst added.
Baird
Baird
Neutral -> Outperform
upgrade
$20 -> $64
2025-10-14
Reason
Baird
Baird
Price Target
$20 -> $64
2025-10-14
upgrade
Neutral -> Outperform
Reason
Baird upgraded Vor Bio to Outperform from Neutral with a price target of $64, up from $20. The firm said it was impressed by the existing dataset surrounding telitacicept, and to that end notes the large amount of data from RemeGen's development of telitacicept in China derisks Vor's ex-China development ambitions. Looking ahead, the firm anticipates investor enthusiasm for telitacicept should continue to build with a pair of late-October data updates in the coming weeks.
Stifel
Stephen Willey
Hold
to
Buy
upgrade
$55
2025-09-23
Reason
Stifel
Stephen Willey
Price Target
$55
2025-09-23
upgrade
Hold
to
Buy
Reason
Stifel analyst Stephen Willey upgraded Vor Bio to Buy from Hold with a $55 price target. The firm notes that its multiple recent management meetings have turned it "incrementally more-positive" on telitacicept prospects across a diverse spectrum of autoimmune diseases, the analyst tells investors in a research note. Telitacicept, which already has three regulatory approvals and two planned regulatory submissions in China, is poised to potentially emerge as a best-in-class dual BAFF/APRIL antagonist, and the firm believes the requisite translation of this success to ongoing myasthenia gravis and aspiring global Phase 3 trials represents attractive biological/clinical and financial risk, the firm added.
H.C. Wainwright
H.C. Wainwright
Neutral
to
Buy
upgrade
$3
2025-06-30
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$3
2025-06-30
upgrade
Neutral
to
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Vor Biopharma Inc (VOR.O) is -1.34, compared to its 5-year average forward P/E of -3.33. For a more detailed relative valuation and DCF analysis to assess Vor Biopharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.33
Current PE
-1.34
Overvalued PE
0.51
Undervalued PE
-7.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.54
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.32
Undervalued EV/EBITDA
-5.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 549.93% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 549.93% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

VOR News & Events

Events Timeline

(ET)
2025-11-10
23:30:25
Vor Bio Prices 10M Share Spot Secondary Offering at $10.00
select
2025-11-10
16:18:34
Bio Secures $100M in Secondary Offering; Price Range Set at $10.00-$12.00
select
2025-11-10
16:07:51
Vor Bio Plans $100 Million Common Stock Offering
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-26NASDAQ.COM
Vor Biopharma (VOR) Receives Upgrade to Buy: Key Information You Need to Know

  • Zacks Rank Upgrade: Vor Biopharma Inc. (VOR) has been upgraded to a Zacks Rank #2 (Buy) due to a significant increase in earnings estimates, indicating a positive outlook for the company's stock price.

  • Earnings Estimate Revisions: The Zacks Consensus Estimate for Vor Biopharma has risen by 420.1% over the past three months, reflecting analysts' growing confidence in the company's future earnings potential.

  • Correlation with Stock Movements: There is a strong correlation between earnings estimate revisions and stock price movements, making the Zacks rating system a valuable tool for investors to identify potential buying opportunities.

  • Market Positioning: The upgrade places Vor Biopharma in the top 20% of Zacks-covered stocks, suggesting it is well-positioned for potential market-beating returns in the near term.

[object Object]
Preview
4.0
11-15NASDAQ.COM
HC Wainwright & Co. Upholds Buy Rating for Vor Biopharma (VOR)

  • Analyst Recommendation: HC Wainwright & Co. has maintained a Buy recommendation for Vor Biopharma, with an average one-year price target of $47.68/share, indicating a potential upside of 373.07% from its current price of $10.08/share.

  • Fund Sentiment: There are currently 67 funds reporting positions in Vor Biopharma, with a slight decrease in ownership by 5.63% over the last quarter, while the average portfolio weight dedicated to VOR has increased by 75.40%.

  • Ownership Breakdown: Major shareholders include Ra Capital Management (11.76% ownership), Vanguard Total Stock Market Index Fund (8.22%), and several other funds with no changes in their holdings over the last quarter.

  • Market Outlook: The put/call ratio for Vor Biopharma is 0.53, suggesting a bullish sentiment among investors, despite a significant decrease in total shares owned by institutions by 92.17% in the last three months.

[object Object]
Preview
6.0
11-14Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Vor Biopharma, Adjusts Price Target to $32

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Vor Biopharma Inc (VOR) stock price today?

The current price of VOR is 8.33 USD — it has decreased -2.12 % in the last trading day.

arrow icon

What is Vor Biopharma Inc (VOR)'s business?

Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.

arrow icon

What is the price predicton of VOR Stock?

Wall Street analysts forecast VOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VOR is 40.00 USD with a low forecast of 9.00 USD and a high forecast of 64.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Vor Biopharma Inc (VOR)'s revenue for the last quarter?

Vor Biopharma Inc revenue for the last quarter amounts to -28.11M USD, decreased -1.42 % YoY.

arrow icon

What is Vor Biopharma Inc (VOR)'s earnings per share (EPS) for the last quarter?

Vor Biopharma Inc. EPS for the last quarter amounts to -53906000.00 USD, increased 131.17 % YoY.

arrow icon

What changes have occurred in the market's expectations for Vor Biopharma Inc (VOR)'s fundamentals?

The market is revising No Change the revenue expectations for VOR for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -78.75%.
arrow icon

How many employees does Vor Biopharma Inc (VOR). have?

Vor Biopharma Inc (VOR) has 159 emplpoyees as of December 05 2025.

arrow icon

What is Vor Biopharma Inc (VOR) market cap?

Today VOR has the market capitalization of 182.52M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free